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ABSTRACT: Shikimate kinase is an essential enzyme in several pathogenic bacteria and it does not have any counterpart 
in human cells, thus making it an attractive target for the development of new antibiotics. The key interactions of the 
substrate and product binding and the enzyme movements that are essential for catalytic turnover of the Mycobacterium 
tuberculosis shikimate kinase enzyme (Mt-SK) have been investigated by structural and computational studies. Based on 
these studies several substrate analogs were designed and assayed. The crystal structure of Mt-SK in complex with ADP 
and one of the most potent inhibitors has been solved at 2.15 Å. These studies reveal that the fixation of the diaxial con-
formation of the C4 and C5 hydroxyl groups recognized by the enzyme or the replacement of the C3 hydroxyl group in the 
natural substrate by an amino group is a promising strategy for inhibition because it causes a dramatic reduction of the 
flexibility of the LID and shikimic acid binding domains. Molecular dynamics simulation studies showed that the product 
is expelled from the active site by three arginines (Arg117, Arg136 and Arg58). This finding represents a previously un-
known key role of these conserved residues. These studies highlight the key role of the shikimic acid binding domain in 
the catalysis and provide guidance for future inhibitor designs. 
INTRODUCTION 
According to the World Health Organization (WHO), 
antibiotic resistance is becoming a public health emer-
gency of unknown proportions.1 Despite the recognized 
need for new antibiotics, the reality is that only two new 
classes of antibiotics have been brought to the market in 
the last three decades.2 Furthermore, there are few anti-
bacterial agents under development to face the challenge 
of multidrug resistance. If action is not taken to address 
these issues, we run the risk of having only a few options 
to treat bacterial infections. Therefore, there is an urgent 
need for the discovery of novel drugs and therapies to 
treat antibiotic-resistant infections and, particularly 
drugs with new mechanisms of action. A greater under-
standing of the behavior of antibiotics in biological sys-
tems is also required. 
One strategy for obtaining new antibiotics is the devel-
opment of compounds that are capable of interfering 
with essential bacterial metabolic processes. One exam-
ple of such a process is the shikimic acid pathway, in 
which chorismic acid is synthesized. This compound is 
the precursor of aromatic amino acids and other metabo-
lites, including folate cofactors, ubiquinone, and vitamins 
E and K.3 This biosynthetic route is present in bacteria, 
fungi, higher plants and certain apicomplexan parasites,4 
particularly Plasmodium falciparum (which causes malar-
ia), Toxoplasma gondii and Cryptosporidium parvum, but 
it is absent in mammals. The essential nature of the shi-
kimic acid pathway in certain microorganisms,5 com-
bined with its absence in mammals, makes it an attrac-
tive target for the development of new antimicrobials and 
herbicides. 
The important features of the shikimic acid pathway have 
not gone unnoticed by the scientific community and in 
recent years a great deal of effort has been focused on the 
development of inhibitors of the enzymes involved in this 
route. Glyphosate [N-(phosphonomethyl)glycine], the 
active ingredient in the well-known herbicides Round-
 
Up,® Zero® and Tumbleweed,®.is a good example. This 
compound is a specific inhibitor of the sixth enzyme of 
the shikimate pathway [5-enolpyruvylshikimate-3-
phosphate (EPSP) synthase]6 with a Ki of 1 µM and it has 
proven to be active in vitro against malaria.4a Structural 
studies have shown that glyphosate occupies the phos-
phoenol pyruvate binding site in the enzyme, mimicking 
an intermediate state of the ternary enzyme substrates 
complex.7 Moreover, De María et al.8 have shown that the 
antimicrobial properties of glyphosate are not only due to 
EPSP inhibition, but also to the high concentrations of 
shikimic acid and protocatechuate that it causes. The 
excess of these compounds result in the inhibition of 
phosphoenolpyruvate carboxylase, an enzyme involved in 
the metabolism of carbohydrates. In addition, Chen et 
al.9 showed that the deletion of the aroK gene, which 
encodes shikimate kinase, the fifth enzyme of the shi-
kimic acid pathway, causes shikimic acid accumulation. 
These facts attracted our attention because it might be 
possible to develop new antimicrobials by inhibition of 
shikimate kinase (SK, EC 2.7.1.71), the enzyme that cata-
lyzes the conversion of shikimic acid (1) into shikimate 3-
phosphate (2) (Scheme 1). In addition, since this enzyme 
is essential in Mycobacterium tuberculosis, Helicobacter 
pylori, Acinetobacter baylyi, Haemophilus influenzae, 
Francisella novicida and Pseudomonas aeruginosa, would 
be an attractive target for the development of new drugs 
against several important bacterial diseases.10 In the work 
described here, we focused on the inhibition of the M. 
tuberculosis enzyme for the development of new chemo-
therapeutic agents against tuberculosis (TB). This disease 
is one of the deadliest infectious diseases for humans and 
it is a primary public health threat.11,12 TB therapy requires 
long periods of treatment (around 6 to 24 months) with 
multiple drugs. This extended treatment leads to poor 
compliance, a factor that promotes resistance develop-
ment. Therefore, there is great interest in the discovery 
and development of alternative TB drugs. 
Scheme 1. Enzymatic conversion of shikimic acid (1) to 
shikimate-3-phosphate (2) catalyzed by the SK enzyme 
 
We report here the design, synthesis and biological eval-
uation of new competitive inhibitors of M. tuberculosis 
shikimate kinase (Mt-SK). Considering that the P-loop, 
which forms the binding site for ATP and ADP and con-
tains the consensus sequence GXXXXGKT/S (with X be-
ing any residue), is rather conserved in many ATP- or 
GTP-binding proteins, we focused on the design of com-
pounds that bind to the shikimic acid binding site.13 The 
design of the reported inhibitors, compounds 39 (Figure 
1) was based on structural and molecular dynamics (MD) 
simulation studies, which helped us to understand the 
determinants of substrate binding affinity and the key 
enzyme movements that are essential for catalytic turno-
ver. These computational studies also allowed us to iden-
tify a previously unknown key role of conserved residues 
Arg117, Arg58 and Arg136 in the release of shikimate-3-
phosphate (2) from the active site, and provided a de-
tailed knowledge of this process. The crystal structure of 
Mt-SK in complex with ADP and one of the most potent 
inhibitors is described along with the results of inhibition 
studies. 
 
Figure 1. Shikimic acid analogs 
 
RESULTS AND DISCUSSION 
Molecular Dynamics Simulation Studies: Substrate 
Binding and Product Release 
Mt-SK enzyme has three domains (Figure 2):14 (1) the 
CORE domain containing a five stranded parallel -
sheets and the P-loop (residues 917), which forms the 
binding site for ATP and ADP; (2) the LID domain (resi-
dues 112124), which closes over the active site and has 
residues that are essential for the binding of ATP; and (3) 
the substrate binding (SB) domain (residues 3361, -
helices 2, 3 and 4), which is responsible for the 
recognition and binding of shikimic acid (1). Circular 
dichroism,13 fluorescence14 and structural15,16 studies sug-
gested that ATP first binds to the enzyme and induces a 
large movement of the LID domain over the active site. 
After this, shikimic acid (1) binds to the active site and 
the LID domain closes over the active site bringing Arg110 
and Arg117 into the ATP and SB domains, respectively.16 
The shikimic acid binds to the active site through direct 
and indirect contacts, mainly via the side chains of Arg136 
and Asp34 and a water network. The phosphoryl transfer 
has been proposed to proceed through a direct in-line 
associative mechanism involving Asp34 as a general base 
to deprotonate the C3 hydroxyl group in 1 for nucleo-
philic attack.16 The resulting pentacovalent intermediate 
would then be stabilized by electrostatic interactions 
with the side chains of Lys15 and Arg117 and Mg2+, which 
may neutralize the developing negative charge. 
MD simulations were carried out in order to analyze the 
key interactions that control the unusual conformation 
required by shikimic acid (1) in the Mt-SK active site and 
 
the enzyme movements that are essential for catalytic 
turnover. To this end, the enzyme complexes of sub-
strates (Mt-SK/ATP/1) and products (Mt-SK/ADP/2) were 
subjected to 10 ns of simulation to analyze the dynamic 
behavior of substrate and product interactions, respec-
tively. 
 
Figure 2. Representation of the overall structure of Mt-SK 
highlighting the three domains: CORE (orange), LID (ma-
genta) and SB (green).
17 
The Michaelis complex. The dynamic behavior of the Mt-
SK/ATP/1 ternary complex was studied first. This com-
plex was generated using the enzyme geometries found 
in the crystal structure of Mt-SK in complex with ADP 
and shikimic acid (1) (PDB code 2IYQ16) and after manual 
replacement of ADP by ATP.18 The results showed that 
there are small movements in the relative positions of 
both substrates in the active site during the simulation 
(10 ns) (Figure 3). Thus, the distance between the γ-
phosphate of ATP and oxygen of the C3 hydroxyl group of 
1 varies between 4.4 and 6.4 Å, mainly due to a to-and-fro 
movement of the SB domain (see supporting infor-
mation). This movement is essential for catalysis because 
it is how the enzyme approximates both substrates to-
gether for the bimolecular reaction. Small movements 
were also observed in the LID domain, but not in the 
relative position of ATP and Arg117, which is essential for 
the binding of ATP, and in the -sheet 3, where the con-
served Asp32 residue is located. The latter is consequence 
of the to-and-fro movement of the SB domain. It has 
been suggested that the hydrogen bond interaction be-
tween the Asp32 and Ser16 side chains, which is located 
close to the -phosphate of ATP, may contribute to the 
approximation of both substrates during the phosphoryl 
transfer reaction.16  
It is noteworthy that, when both substrates are close to-
gether, the guanidinium group of Arg117 (NH2 and NE) 
forms two hydrogen bonds with the γ-phosphate of ATP 
and water molecules are not observed between the two 
substrates. This finding suggests that this residue might 
also act as a Lewis acid during the enzymatic catalysis, by 
activating and positioning the phosphoryl group of ATP 
for nucleophilic attack by the C3 hydroxyl group and may 
also stabilize the phosphoryl oxygen atoms in the transi-
tion state. 
As has been suggested, the substrate remains strongly 
bound to the active site by a salt bridge with the guanidi-
um group of Arg136 and by hydrogen bonding between 
the side chain of the conserved Asp34 residue and the C4 
hydroxyl group. These interactions do not change signifi-
cantly during the simulation (10 ns), suggesting that the 
substrate is strongly anchored to the enzyme active site 
through the interactions. By contrast, the hydrogen 
bonding between the hydroxyl group at C3 and the Asp34 
side chain, which is observed in numerous crystal struc-
tures,14,16,19 is easily lost during the simulation, particularly 
when both substrates are very close (see supporting in-
formation). Moreover, the C3 hydroxyl group is arranged 
in an equatorial disposition in order to proceed with the 
phosphoryl transfer reaction by forcing the axial disposi-
tions of C4 and C5 hydroxyl groups. The latter arrange-
ment is wonderfully achieved by hydrogen-bonding in-
teractions with the conserved residues Asp34 and Gly80 
and with three water molecules. Specifically, the C4 hy-
droxyl group is fixed in an axial arrangement by hydrogen 
bonding with the side chain of the conserved Asp34 and 
with a structural water molecule (WAT1), which does not 
exchange with the solvent throughout the whole dynamic 
process (see supporting information). WAT1 is anchored 
through a set of hydrogen-bonding interactions with the 
side chains of the conserved amino acids Glu61 and Arg58 
and the main-chain amide of the conserved residue Gly81 
(Figure 3a). Asp34 and Glu61 are always bridged by an 
exchangeable water molecule, probably to avoid repul-
sion between these two residues.  
This exquisite control of the axial position of the C4 hy-
droxyl group with one water molecule, the position of 
which is frozen by the conserved residues Glu61, Arg58 
and Gly80, is also achieved for the apolar pocket generat-
ed by the conserved Phe49 and Phe57 residues located in 
-helices 3 and 4, which isolates this important recog-
nition part of the enzyme from the solvent. On the other 
hand, the axial disposition of the C5 hydroxyl group is 
fixed by two water molecules that are exchangeable with 
the solvent (Figure 3 and see supporting information). 
Both water molecules create a water bridge between the 
C1 carboxylate group and the C5 hydroxyl group that 
freeze this conformation. The water molecule closest to 
the C5 hydroxyl group interacts with the NH main chain 
of Leu119 located in the LID domain. Analysis of the ami-
no acid sequence in various SK (see supporting infor-
mation) reveals that these water molecules are always 
embedded in an apolar region, specifically Pro11, Leu119 
and Leu132 for Mt-SK, which appears to contribute great-
ly to their arrangement. Together with Arg117, this con-
tributes to close the active site tightly. By forcing the 
axial disposition of the C4 and C5 hydroxyl groups, the 
enzyme controls the equatorial disposition of the C3 hy-
droxyl group and allows its selective phosphoryl-transfer 
reaction. The hydrogen bonding interaction with the NH 
main chain amide of Gly80, which remains stable during 
the simulation, allows the appropriate orientation of the 
oxygen lone pair of the C3 hydroxyl group for the phos-
phoryl-transfer reaction.  
 
     
Figure 3. Michaelis complex: a) and b) two views of the relevant binding interactions of shikimic acid (1) in the active site 
of Mt-SK; c) comparison of the several snapshots of the LID and SB domains and the position of both substrates (ATP, 1) 
of Mt-SK/ATP/1 complex during 10 ns of MD simulations. Note that significant movements of these domains are not ob-
served and that they remain closed during the simulation. Relevant side chain residues are shown and labeled. 
     
     
Figure 4. Snapshots of shikimate-3-phosphate (2) (yellow) release from the active site of Mt-SK obtained by MD simulations: (a) 
after 0.02 ns (yellow); (b) after 0.08 ns (orange); (c) after 0.16 ns (magenta); (d) 2.4 ns (green); (e) after 10 ns (blue); (f) superposi-
tion of a–e. Note the large conformational changes of the LID and the -helices 3 and 2 of the SB binding domains during 
product release. Significant changes were not observed in the ADP binding site. Relevant side chain residues are shown and 
labeled. 
Enzyme products complex. In order to understand the 
structural changes responsible for triggering the release 
of the product from the active site, the dynamic behavior 
of the Mt-SK/ADP/2 ternary complex was studied. The 
results showed that the Asp34 side chain moves away 
from the C3 phosphate group in 2 as soon as the dynamic 
simulation starts (20 ps), probably due to the electro-
static repulsion caused by the phosphate group, which is 
now close (Figure 4). More importantly, the Arg117 side-
chain located of the LID domain progressively moves 
toward the C3 phosphate group in 2 (0.8 ns). This strong 
salt-bridge interaction between the phosphate group in 2 
and the guanidinium group of Arg117 triggers the release 
of the product from the active site. Thus, by pulling on 
the phosphate group in 2, Arg117 causes the breakage of 
the favorable interactions of the product with the active 
site residues, particularly the salt-bridge interaction be-
tween the C1 carboxylate group and the guanidinium 
group of Arg136. 
As a result, a significant conformational change in the 
product and a large movement of the SB domain takes 
place (up to 10 Å for -helix 3). Thus, as the product 
 
loses the key interactions that control the afore-
mentioned kinetic conformation required for catalysis, 
which is favored by the large movement of the SB do-
main, it quickly undergoes a 45° turn and a conforma-
tional change to its thermodynamically favorable con-
formation, i.e. with the C4 and C5 hydroxyl groups locat-
ed in a pseudo-equatorial disposition. As the product 
moves away from the Arg117 residue, the Arg58 and 
Arg136 residues become responsible for expelling the 
product from the active site. With the product on the 
way out of the active site, the SB domain recovers its po-
sition but it is not such closed form as after substrate 
binding (2 Å away). During product release, the LID 
domain also undergoes large movements to allow the 
Arg117 and Arg136 side chains to be displaced by up to 6 Å 
in order to expel the product from the active site. Moreo-
ver, it is noted that the hydrogen bond that enzyme uses 
to bring together the SB and nucleotide domains is rapid-
ly broken during the simulation and the Asp32 side chain 
only interacts now with the NH main-chains of Asp34 
and Val35, which are located in the SB domain. 
Taken together, our MD simulation studies highlight that 
there are four key structural factors required for the ca-
talysis: (1) the C4/C5 diaxial conformation of shikimic 
acid (1); (2) a closed form of the LID domain to allow 
activation of the γ-phosphate of ATP and stabilization of 
the transition state by the guanidinium group of the 
Arg117 side chain; (3) a closed form of the SB domain in 
order to bring the substrates together for the phosphoryl-
transfer reaction and to isolate the substrate within an 
apolar cavity; (4) a flexible LID and SB domain for prod-
uct release. On the basis of this knowledge, we decided to 
study the possible inhibition of the SK enzyme by com-
pounds capable of disturbing these key structural factors 
and impeding essential enzyme movements. For this 
purpose, we studied the biological activity of compounds 
39 (Figure 1), which were designed to fix the required 
diaxial conformation, to promote electrostatic interac-
tions with the conserved Asp34 side chain and/or γ-
phosphate group of ATP and/or to reduce the flexibility 
of the SB and LID domains. Moreover, the specificity of 
the reaction was studied with 3-epi-shikimic acid (8). 
Synthesis of Compounds 34 
The synthesis of conformationally restricted shikimic 
acid derivatives 34 involved the formation of the ether 
bridge by ring-closing metathesis of allyl vinyl derivative 
15 and implies the incorporation of the vinyl moiety in 15 
by 1,2-nucleophilic addition of previously reported enone 
10,20 which is prepared in two steps from (–)-shikimic 
acid (1) (Scheme 2 and supporting information). Follow-
ing our synthetic strategy, the synthesis of allyl vinyl de-
rivative 15 was first attempted by nucleophilic addition of 
vinyl magnesium bromide to enone 10 and subsequent 
formation of the acetonide 14. Vinyl derivative 11 was 
diastereoselectively obtained in 72% yield. The regiose-
lectivity of the reaction was confirmed by NOE experi-
ments. Inversion of the signal of H6 led to enhancement 
of the signal for the H1´ vinyl group (3.1%). However, the 
conversion of vinyl derivative 11 to the protected alkene 
14 was proved difficult because, under standard mild 
acidic conditions, compound 11 easily undergoes a 1,3-
transposition to give allyl alcohol 12.  
Scheme 2a 
 
aReagents and conditions:  (a) H2C=CHMgBr, THF, ‒78 °C 
to RT. (b) TFA/H2O (20:1), 0 °C. (c) HC≡CMgBr, THF, ‒78 
°C to RT. (d) C(Me)2(OMe)2, acetone, CSA (cat), Δ. (e) H2, 
Lindar catalyst (cat), EtOH. (f) AllylOCO2Me, Pd2(dba)3 
(cat), dppb, THF, Δ. 
 
Reasoning that this reaction could be avoided by using 
the corresponding alkyne derivative, the synthesis of 
vinyl allyl 15 via alkyne 16 was carried out as shown in 
Scheme 2. Treatment of enone 10 with ethynyl magnesi-
um bromide at 78 °C afforded a chromatographically 
separable mixture of the two hydroxyl alkynes 16, the 
stereochemistry of which was confirmed by the NOE 
experiments. Thus, inversion of the signal of the axial H1 
in 16S led to enhancement of the signal for OH group 
(1.3%). Deprotection of 16S with aqueous trifluoroacetic 
acid followed by cis-1,2-diol protection of the resulting 
triol 17 afforded acetonide 18. Catalytic hydrogenation of 
alkyne 18 using Lindar catalyst gave the desired alkene 14 
in 82% yield. Finally, allylation of 14 was achieved by tre-
atment with allyl methyl carbonate and a catalytic 
amount of Pd2(dba)2/dppb to give allyl vinyl derivative 15 
in 77% yield. 
Ring-closing metathesis of allyl vinyl derivative 15 in the 
presence of second-generation Grubbs catalyst in toluene 
 
at room temperature readily afforded bicyclic derivative 
19 in 80% yield (Scheme 3). Catalytic hydrogenation of 
alkene 19 using Lindar catalyst in the presence of pyri-
dine gave the desired saturated alkane 21 in 75% yield. 
Finally, bicyclic derivatives 19 and 21 were converted into 
the desired acids 3 and 4, respectively, in two steps. 
Deprotection of the acetal groups in 19 and 21 with HCl 
was followed by basic hydrolysis of the resulting esters 20 
and 22, respectively, and subsequent protonation with 




Reagents and conditions:  (a) 2nd generation Grubbs´ cata-
lyst, PhMe, RT. (b) EtOH, HCl (6 M), 60 °C. (c) 1. LiOH (aq.), 
THF, RT. 2. Amberlite IR-120 (H
+
), RT. (d) H2, Lindar catalyst 
(cat), Py, MeOH. 
 
Synthesis of Compounds 59 
The synthesis of compounds 56 was achieved from pre-
viously reported bromide 2321 (Scheme 4 and supporting 
information). TBS protection with TBSOTf and pyridine 
followed by cross-coupling of the resulting bromide 24 
with Ni(CO)(PPh3)2
22 in the presence of ethanol afforded 
the desired ethyl ester 25 in 75% yield. Deprotection of 
the TBS groups with TBAF gave the diol 26, which was 
converted to the desired (6R)-6-hydroxyshikimic acid 
(6)23 as acid 3 from 19. Diol 26 was converted into the 
desired acid 5 as compound 6 from ethyl ester 27. Finally, 
3-epishikimic acid (8) and (3R)- (7)24 and (3S)-3-
aminoshikimic acids (9) were prepared from shikimic 
acid (1) using slight modifications of previously reported 
protocols (see supporting information). 
Inhibition Activity of Compounds 39 
All the reported shikimic acid analogs were assayed 
against Mt-SK. Enzyme activity was measured by UV 
monitoring of the ADP formation by coupling the re-
leased of ADP to the oxidation of NADH using pyruvate 
kinase (PK) and lactate dehydrogenase (LDH) as coupling 
enzymes. The disappearance of NADH by oxidation to 
NAD during PK-LDH activity was monitored at 340 nm.  
All of the compounds were found not to be substrates for 
this enzyme, including 3-epi-shikimic acid (8), which 
illustrates the aforementioned enzyme specificity. These 
compounds were then assayed in the presence of shi-
kimic acid (1) and ATP for their inhibitory properties 
against Mt-SK and they proved to be reversible competi-
tive inhibitors of the enzyme. The inhibition data (Ki) are 
summarized in Table 1. The Ki values were obtained from 




Reagents and conditions:  (a) TBSOTf, DCM, Py, 0 °C. (b) 
Ni(CO)(PPh3)2, DIPEA, EtOH, 80 °C. (c) TBAF, THF, 0 °C. (d) 
1. LiOH (aq), RT; 2. Amberlite IR-120 (H
+
), RT. (e) HCl (6 M), 
60 °C. 
Table 1. Ki values of compounds 39 against Mt-SK
a 
Compound Ki (µM) 
3 62  1 
4 46  2 
5 1050  17 
6 792  16 
7 62  1 
8 >4000 
9 65  1 
aAssay conditions: Tris.HCl (100 mM, pH 7.7), ATP (2.5 
mM), NADH (0.2 mM), PEP (1 mM), MgCl2 (5 mM), 
KCl (100 mM), lactate dehydrogenase/pyruvate kinase 
(2.8 units), 25 °C. Km (1) = 544 µM. 
Bicyclic compounds 34 and aminoshikimic acids 7 and 9 
proved to have Ki values below the Km. Saturated bicycle 
4 proved to be the most potent inhibitor of the series, 
with a Ki of 46 µM. Aminoshikimic acids 7 and 9 and 
unsaturated bicycle 3 showed similar inhibition activities, 
with Ki in the range 6265 µM. 
In order to obtain further details of the binding mode of 
these inhibitors in more detail, the crystal structure of 
Mt-SK in complex with one of the most potent inhibitors 
reported here, bicycle 3, and ADP was solved at 2.15 Å. 
The binding modes of compounds 49 with Mt-SK were 
first studied using GOLD 5.0.125 with our previously ob-
 
tained model of the Michaelis complex (see before) and 
they were further analyzed by MD simulation studies, 
which are discussed below. 
Binding Mode of Compounds 39 
Crystal structure of Mt-SK/ADP/3 ternary complex. The 
crystal structure of Mt-SK with the bicycle 3 and ADP, 
obtained by co-crystallization, was determined at 2.15 Å. 
Crystals were cryoprotected with crystallization solution 
(see experimental section) supplemented with 25% glyc-
erol and flash-frozen by rapid immersion in liquid nitro-
gen. X-ray diffraction data were collected from crystals 
cryo-cooled in a stream of cold nitrogen gas (100 K) at 
ambient pressure using synchrotron radiation and were 
subsequently processed. The crystallographic structure 
was solved by molecular replacement, using the structure 
of Mt-SK previously described bound to shikimic acid (1) 
and sulfate (PDB entry 2G1K)19 as a search model and the 
structure was refined (Figure 5). Although ATP was used 
in the crystallization solution, only ADP was identified in 
the structure, which is not surprising because ATP spon-
taneously hydrolyzes to ADP and phosphate. A summary 
of the statistics following data reduction and processing 
is given in Table 2. 
The Mt-SK/ADP/3 ternary complex crystallized with 
three copies in the asymmetric unit (designated as chains 
A, B and C) (Figure 5). The three crystallographically 
independent copies superimpose well onto each other, 
with rms differences between 0.2350.250 Å for 152-154 
superposed Cαatom pairs.26 The main differences be-
tween these chains are located in loop corresponding to 
residues 149155, mainly in the position of Arg153. Com-
parison of Mt-SK/ADP/3 and Mt-SK/ADP/2 (PDB entry 
2IYZ16) shows that the two structures are virtually identi-
cal (0.307 Å, 0.252 Å and 0.278 Å root mean square differ-
ence after superposition of 162, 153 and 161 Cαatom pairs 
from chain A, B and C, respectively) (see supporting in-
formation). The aromatic and sugar moieties of ATP are 
displaced by 1 Å relative to their corresponding posi-
tions in PDB entry 2IYZ and superimpose well in Mt-
SK/ADP/1 ternary complex (PDB entry 2IYQ16) (see sup-
porting information). These small differences are a con-
sequence of variations in the position of the loop close to 
ATP/ADP, which is not fully resolved in PDB entry 2IYZ. 
However, differences were not observed in the position of 
the diphosphate groups of ADP. 
Unbiased, calculated, electron density maps showed clear 
electron density for ADP and the inhibitor molecule 3 
(Figure 5a). The cyclohexene ring of inhibitor 3 occupies 
approximately the same site as shikimate-3-phosphate (2) 
or shikimic acid (1) in PDB entries 2IYZ and 2IYQ,16 re-
spectively. As the natural substrate, the bicycle 3 binds to 
the active site by a salt-bridge between its carboxylate 
group and the guanidinium group of Arg136 along with a 
bidentate hydrogen bond between the carboxylate group 
of Asp34 and the C3 and C4 hydroxyl groups of the inhib-
itor. Moreover, the C3 hydroxyl group interact by hydro-
gen bonding with the amide nitrogen of Gly80. The lig-
and also interacts with the enzyme through indirect con-
tacts via several bridging water molecules. Thus, the C4 
hydroxyl group is anchored in the active site by interac-
tion with Glu61, Arg58 and Gly81 by hydrogen bonding 
with the structural water molecule (WAT2020). The con-
served Lys15 residue interacts with the C3 hydroxyl group 
of 3 via a bridging water molecule (WAT2006). Finally, 
two water molecules make a water bridge between the 
carboxylate group (WAT2041) and the oxygen atom of 
the C3C5 ether bridge (WAT2041 and WAT2031). 
 
 
Figure 5. (a) Unbiased electron density for inhibitor 3 and 
ADP in ternary complex Mt-SK/ADP/3 (chain B). From the 
model obtained by molecular replacement and before inclu-
sion of the inhibitor molecule, refinement was performed to 
obtain unbiased density for the inhibitor molecule and other 
model changes. A maximum-likelihood weighted 2Fo – Fc 
map contoured at 1σ is shown up to 1.6 Å around the inhibi-
tor molecule (green). The final model including the inhibitor 
molecule 3, is superimposed onto the map. (b) Interactions 
of inhibitor 3 with Mt-SK (grey). Polar (orange) and lipo-
philic (dark grey) interactions between 3 and the Mt-SK 
(grey) are shown. Relevant residues are shown and labeled.  
Notably, the hydrogen bonding interaction of one of these 
water molecules (WAT2031) with the amide nitrogen of 
Leu119, together with the lipophilic interactions of the C3C5 
ether bridge with the carbon side-chain of Arg117 and the 
carbon ring of Pro118, keep the LID closed. In fact, when the 
Mt-SK/ADP/3 ternary complex was subjected to 10 ns of 
simulation in order to analyze the dynamic behavior of the 
latter interactions, the relative position of ligand 3, Arg117 
and Pro118 in the active site did not change significantly. This 
 
finding suggests that the aforementioned interactions pro-
vide a very stable closed form of the loop. 
Table 2. Crystallographic data collection and refinement 
statistics for the Mt-SK complex with ADP and inhibitor 
3a 
Data processinga Mt-SK/ADP/3 
space group P21 
cell parameters (a, b, c), Å 40.65, 60.96, 89.98 (β = 
95.44°) 
wavelength (Å) 0.9798 
detector Dectris Pilatus3 6M 
observed reflectionsb 75346 (8274)c 
resolution range (Å) 28.852.15 (2.272.15) 
Wilson B (Å2) 21.0 
multiplicity 3.3 (3.0) 
completeness 0.956 (0.794) 
Rmerge 0.083 (0.344) 
Refinementd  
resolution range (Å) 28.872.15 (2.272.15) 
reflections used in refine-
mentc 
21698 (2625) 
reflections used for Rfree 1165 (138) 
R factore 0.172 (0.231) 
Rfree
f 0.235 (0.316) 
rmsd (bonds (Å)/angles 
(deg)) 
0.014/1.7 








Ramachandran statisticsg (%) 98.0/100.0 
PDB accession code 4BQS 
aResults from SCALA.27 bNo sigma cut-off or other re-
strictions were used for inclusion of reflections. cValues 
in parentheses are for the highest resolution bin, where 
applicable. dResults from REFMAC.28 eR-factor = 
||Fobs(hkl)| - |Fcalc(hkl)|| / |Fobs(hkl)|. fAccording to 
Brünger.29 gAccording to the program MOLPROBITY.30 
The percentages indicated are for residues in favored 
and total allowed regions, respectively. 
 
Saturated Bicycle 4. Docking and MD simulation studies 
showed that, in general, the two bicyclic derivatives 3 and 
4 should have a similar binding mode. The main differ-
ences that would arise from the reduction of the double 
bond of the C3C5 ether bridge in 3 are more lipophilic 
interactions of the ether bridge with the conserved resi-
dues Arg117 and Pro118 (Figure 6a). The change in hy-
bridation would mean that the C3C5 bridge would be 
located closer to the carbon side chain of conserved 
Arg117 and the carbon ring of conserved Pro118. As a con-
sequence, the flexibility of the LID domain would be fur-
ther reduced in comparison with that in the unsaturated 
bicycle 3. In addition, a very effective closure of the SB 
domain seems to take place. Both effects would reduce 
the flexibility of the two domains and this might explain 
its higher inhibitory potency. 
3-Aminoshikimic acids 7 and 9. The studies carried out on 
(3R)- (7) and (3S)-3-aminoshikimic acids (9) showed that 
in both cases the cyclohexene ring would bind in a simi-
lar way to the natural substrate, even in the case of ligand 
9, which has the opposite stereochemistry at C3 (Figures 
6b-c). This is because both C3 amino groups would inter-
act with the -phosphate of ATP through a strong elec-
trostatic interaction. In both cases, the -phosphate of 
ATP and the amino group remain very close during the 10 
ns of simulation (3.03.5 Å between heavy atoms) and in 
general, both ternary complexes proved to be very stable 
as significant changes were not observed. This electro-
static interaction favors that the nucleotide and SB do-
mains remain very close. In fact, the hydrogen bond be-
tween the side-chains of Ser16 and Asp32 residues is 
maintained 1.51.7 Å during the simulation. As a conse-
quence, the flexibility of the LID and the SB domains is 
dramatically reduced. Notably, in the case of 3-
epiaminoshikimic acid (9) the active site is even more 
closed than that in the natural substrate and its epimer 7. 
Unlike (3R)-3-aminoshikimic acid (7), 3-epi-
aminoshikimic acid (9) lacks the possible hydrogen-
bonding interaction with the side-chain of conserved 
Asp34 and the water network would be displaced by 
about 1‒1.5 Å from the C1 carboxylate group and the C5 
hydroxyl group as a result of the axial arrangement of the 
amino group. Despite this, the C5 hydroxyl group would 
remain axially fixed through a strong intramolecular hy-
drogen-bonding interaction with the C3 amino group. It 
seems that the overall binding interactions of both ami-
noshikimic acids are quite similar and the interaction 
with the -phosphate of ATP seems to be crucial in freez-
ing their binding to the active site, a situation that may 
explain their similar inhibitory potencies. 
Hydroxyshikimic acid 6. The MD simulation studies car-
ried out with (6R)-6-hydroxyshikimic acid (6) showed 
that replacement of the pro-R hydrogen in 1 by a hydrox-
yl group caused significant changes in the water network 
and in the recognition of the C1 carboxylate group (Figure 
6d). As a consequence, the ligand caused large move-
ments in the α-helices α2 and α3 of the SB domain.  
Thus, an opening of the SB domain by nearly 6 Å is ob-
served (see supporting information). With the opening of 
the SB domain, the ligand would undergo a conforma-
tional change to the thermodynamically more stable con-
formation, i.e. with C4 and C5 hydroxyl groups in the 
pseudo-equatorial conformation. This binding confor-
mation of 6 and the greater flexibility of the SB domain 




      
       
Figure 6. Binding mode of bicycle (4, a), (6R)-6-hydroxyshikimic acid (6, b), (3R)-3-aminoshikimic acid (7, c) and (3S)-3-
aminoshikimic acid (9, d) obtained by MD simulation studies. Comparison of the binding mode of bicycles 3 and 4 and 3-
aminoshikimic acids 7 and 9 with the natural substrate are shown in figures e and f, respectively. Relevant side chain residues 
are shown and labeled. Polar (blue) and lipophilic (orange) interactions between ligands and the Mt-SK are shown. 
The results suggest that the axial incorporation of a hy-
droxyl group at C6 of 1 and, in general, a group able to 
form a hydrogen bond might not increase the binding 
affinity because it does not favor a closed form of the SB 
domain. Similar behavior was observed with ligand 5. 
The binding free energies of the ligands were calculated 
using MM/PBSA31 approach in explicit water (GB) as im-
plemented in Amber. The results suggested that 3-
aminoshikimic acids 7 and 9 and the bicyclic derivatives 3 
and 4 have higher affinity for the enzyme than the natu-
ral substrate, as it was found experimentally. Further 
functionalization of the reported inhibitors is required to 
improve their inhibition potency. The incorporation of 
additional functional groups into the core structure of 
bicyclic compounds 34 and 3-aminoshikimic acids 7 and 
9 should provide extra binding interactions with the ac-
tive site and therefore lower inhibition constants. Such 
modifications are undertaken in our laboratories. 
CONCLUSIONS AND FINAL REMARKS 
The key interactions of substrate binding and the enzyme 
movements that are essential for catalytic turnover of 
shikimate kinase from M. tuberculosis have been investi-
gated by structural and computational studies. MD simu-
lation studies carried out with the enzyme/substrate 
complex revealed the key binding interactions and the 
movements of the SB and LID domains for recognition of 
the unfavorable conformation of shikimic acid (1) and 
showed that this conformation enables a selective phos-
phorylation of the C3 hydroxyl group in 1. The study of 
the dynamic behavior of the enzyme/product complex 
allowed us to identify the key residues and domain 
movements responsible for the release of shikimate-3-
phosphate (2) from the active site. Thus, shikimate-3-
phosphate (2) is expelled from the active site by three 
arginine residues (Arg117, Arg136 and Arg58), which un-
veiled a previously unknown key role of these conserved 
residues. Arg117 triggers the process by forming a strong 
electrostatic interaction with the C3 phosphate group in 
2. The latter interaction causes destabilization of the 
product in the active center and a conformational change 
of the product occurs, which in turn leads a large opening 
of the SB domain. The inhibition of this enzyme was in-
vestigated with conformationally restricted shikimic acid 
analogs 34, aminoshikimic acids 7 and 9 and hydroxy 
derivatives 5 and 6. All of the compounds proved to be 
competitive reversible inhibitors of the enzyme. Saturat-
ed bicycle 4 proved to be the most potent inhibitor of the 
series, with a Ki of 46 µM. Aminoshikimic acids 7 and 9 
and unsaturated bicycle 3 showed a similar inhibition 
activity, with Ki values in the range 6265 µM. 
The crystal structure of the enzyme in complex with ADP 
and one of the most potent inhibitors, bicycle 3, was 
solved at 2.15 Å. The crystal structure and the MD simula-
tion studies reported here show that the lipophilic inter-
actions of the C3C5 ether bridge in 3 with the carbon 
side-chain of Arg117 and the carbon ring of Pro118 are key 
factors in reducing the flexibility of the LID domain. In 
addition, the conformational rigidity provided by the C3-
C5 bridge allows the ligand to be anchored to the active 
 
site and keeps the SB domain close to the ligand. The 
reduction of the double bond of the C3C5 ether bridge 
in 3 enhances both effects and this might explain the 
higher inhibition potency of saturated bicycle 4. 
The replacement of the C3 hydroxyl group in the natural 
substrate by an amino group also proved to be a promis-
ing strategy to inhibit the enzyme. Regardless of the con-
figuration of the C3 center, both amino groups interact 
with the γ-phosphate of ATP by strong electrostatic in-
teractions that seem to be crucial in freezing their bind-
ing to the active site. As a consequence, the flexibility of 
the LID and the SB domains is dramatically reduced. By 
contrast, the incorporation of a hydroxyl group at C6 in 1 
favors large movements of the SB domain and this allows 
a conformational change of the ligand to the thermody-
namic conformer, which is not recognized by the en-
zyme. The results described here show that, since the SK 
enzyme is wonderfully designed to recognize a thermo-
dynamically less stable conformation of the natural sub-
strate, those compounds capable of maintaining the con-
formation recognized by the enzyme and also causing a 
reduction in the mobility of the LID and/or SB domains, 
represent a good strategy for the development of enzyme 
inhibitors. Although virtual screening studies suggested 
several molecules as potential inhibitors of the Mt-SK 
enzyme,32 to our knowledge the compounds described 
here are the first inhibitors developed against Mt-SK. The 
results presented here improve our understanding of 
some of the determinants of binding affinity and product 
release and provide guides for the next high-affinity gen-
eration of inhibitors of the SK enzyme, which is an attrac-
tive target for the development of new drugs against sev-
eral important bacterial diseases. 
EXPERIMENTAL SECTION 
Molecular dynamics simulations. Ligand minimiza-
tion. Ligand geometries were minimized using a restrict-
ed Hartree–Fock (RHF) method and a 6–31G(d) basis set, 
as implemented in the ab initio program Gaussian 09.33 
The resulting wavefunctions were used to calculate elec-
trostatic potential-derived (ESP) charges employing the 
restrained electrostatic potential (RESP)34 methodology, 
as implemented in the assisted model building with en-
ergy refinement (AMBER)35 suite of programs. The miss-
ing bonded and non-bonded parameters were assigned, 
by analogy or through interpolation, from those already 
present in the AMBER database (GAFF).33,36  
Generation and minimization of ternary complexes. Simu-
lations were carried out using the enzyme geometries 
found in the crystal structures of Mt-SK in complex with 
shikimic acid (1) and ADP (PDB code 2IYQ16) and shiki-
mate-3-phosphate (2) and ADP (PDB code 2IYZ16). The 
first one was used for the Michaelis complex and the lat-
ter one for the products complex. The coordinates of the 
unsolved residue Arg152 in PDB code 2IYZ were incorpo-
rated from PDB code 2IYQ. ATP and Mg2+ were manually 
docked into the active site after superposition with PDB 
code 2IYW16. Crystallographic water molecules were 
maintained in both complexes except for those coordi-
nated with the -phosphate of ADP in PDB 2IYQ. For the 
Michaelis complex, the crystallographic water molecules 
coordinated with the γ-phosphate of ATP and Mg2+ in 
PDB 2IYW were also added. Protein N- and C-terminal 
groups were modified as N-acetyl and N-methyl amide 
derivatives, respectively. Computation of the protonation 
state of titratable groups at pH 7.0 were carried out using 
the H++ Web server.37 Addition of hydrogen and molecu-
lar mechanics parameters from the ff03 and GAFF force 
fields, respectively, were assigned to the protein and the 
ligands using the LEaP module of AMBER 10.0.35-36,38 ATP, 
ADP and Mg2+ parameters used with the AMBER force 
field were included.39,18 All terminal hydrogens were first 
minimized in vacuo (2000 steps, half of them steepest 
descent, the other half conjugate gradient). For the prod-
ucts/enzyme complex, sequence DTNRRNP, in which 
missing Arg152 was introduced, was previously mini-
mized in vacuo (2000 steps, half of them steepest de-
scent, the other half conjugate gradient) to eliminate 
potential tensions generated. Energy minimization using 
the implicit solvent GB model was then carried out in 
stages, starting with ligand (1000 steps, half of them 
steepest descent, the other half conjugate gradient), pro-
tein side chains (1000 steps, idem) and finally the entire 
complex (1000 steps, idem). A positional restraint force 
constant of 50 kcal mol-1 Å-2 was applied to those unmin-
imized atoms in each step during all calculations. The 
complex was neutralized by addition of chloride ions and 
immersed in a truncated octahedron of 5300 TIP3P wa-
ter molecules.35,40,41 
Simulations. MD simulations were performed using the 
sander module from the AMBER 10.0 or 11.0 suite of pro-
grams. Periodic boundary conditions were applied and 
electrostatic interactions were treated using the smooth 
particle mesh Ewald method (PME)42 with a grid spacing 
of 1 Å. The cutoff distance for the non-bonded interac-
tions was 9 Å. The SHAKE algorithm43 was applied to all 
bonds containing hydrogen, using a tolerance of 10-5 Å 
and an integration step of 2.0 fs. Minimization was car-
ried out in three steps, starting with the octahedron wa-
ter hydrogens, followed by solvent molecules and sodium 
counterions and finally the entire system. The minimized 
system was heated at 300 K (1 atm, 25 ps, a positional 
restraint force constant of 50 kcal mol–1 Å–2). These initial 
harmonic restraints were gradually reduced to 5 kcal mol–
1 Å–2 (10 steps) and the resulting systems were allowed to 
equilibrate further. Unrestrained MD simulations were 
carried out for 10 ns (500 steps). System coordinates were 
collected every 2 ps for further analysis. A slow-cooling 
MD simulation with constraints of 5 Kcal mol–1 Å–2 was 
performed (6 steps until 273 K). Finally, minimization of 
the entire complexes was performed with constraints of 5 
Kcal mol-1 Å-2.  
Crystallization and structure determination of the 
Mt-SK/ADP/3 ternary complex. A solution of freshly 
purified Mt-SK (1.5 mg mL–1)14 was concentrated to 14 mg 
mL–1 in 20 mM Tris.HCl pH 7.4, 40 mM KCl and 0.1% 
sodium azide. Crystallization was carried out with con-
centrated protein solution, 5 mM ATP and 0.25 M of 
 
compound 3. ATP and compound 3 were added to ali-
quots of the concentrated protein solution to give solu-
tions of approximately 7 and 20 equivalents of ATP and 
inhibitor per protein monomer, respectively. Prism-
shaped crystals of up to 0.10 mm × 0.02 mm × 0.02 mm 
were obtained in sitting drops after three months of va-
por diffusion against 0.15 mL reservoirs containing 20% 
(w/v) poly(ethyleneglycol) 3350, 0.5 M LiCl and 100 mM 
Tris.HCl pH 7.8. Drops contained 2.0 μL of pro-
tein/ATP/inhibitor solution mixed with 2.0 μL of reser-
voir solution. 
Crystals were harvested in reservoir solution supple-
mented with 25% (w/v) glycerol, mounted into a cry-
oloop and flash-frozen by rapid immersion in liquid ni-
trogen. X-ray diffraction data were collected on beamline 
I02 (Synchrotron Diamond, Oxfordshire, UK) from crys-
tals maintained at 100 K. The data were processed, scaled 
and analyzed using XDS,44 SCALA27 and other programs 
within the CCP4 software suite.45 The structure of Mt-
SK/ADP/3 ternary complex was solved by molecular re-
placement using the program MOLREP46 with a search 
model generated from PDB entry 2G1K19 from which lig-
ands and solvent were removed. The structure and geo-
metrical restraints of the inhibitor were generated with 
the PRODRG2 server47. Ligands were manually placed 
during the model building, which was performed with 
COOT.47 Reflections for the calculation of Rfree29 were 
selected randomly. Refinement of the model was per-
formed with REFMAC28 and final structure validation was 
performed with MOLPROBITY.30 Data collection, refine-
ment and model statistics are summarized in Table 2.  
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